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Abstract
Background Research in rodents demonstrated that psy-
chological stress increases circulating levels of alanine
transaminase, aspartate transaminase, and alkaline phos-
phatase reflecting liver injury. Moreover, chronic post-
traumatic stress disorder and transaminases predicted
coronary heart disease.
Aims To investigate the hypothesis that severity of post-
traumatic stress disorder following myocardial infarction
would prospectively relate to liver enzymes.
Methods Study participants were 24 patients (mean
59 ± 7 years, 79% men) with an interviewer-rated diag-
nosis of posttraumatic stress disorder caused by an index
myocardial infarction 3 ± 3 months before. After a mean
follow-up of 26 ± 6 months, patients had a clinical inter-
view to reassess posttraumatic stress disorder severity, a
medical history, and blood collected to determine liver
enzymes.
Results Total posttraumatic stress disorder symptoms
assessed at study entry prospectively predicted plasma
levels of alanine transaminase (r = .47, p = .031) and
alkaline phosphatase (r = .57, p = .004), but not of
aspartate transaminase (p = .15), controlling for follow-up
duration and antidepressant use. Total posttraumatic stress
disorder symptoms assessed at follow-up were associated
with alanine transaminase (r = .72, p = .004), aspartate
transaminase (r = .60, p = .018), and alkaline phospha-
tase (r = .64, p = .001) in the 16 patients who had
maintained diagnostic posttraumatic stress disorder, but not
in all 24 patients.
Conclusions The severity of posttraumatic stress disorder
following myocardial infarction was associated with mild
increase in liver enzyme levels, suggesting that chronic
psychological stress relates to hepatic damage in humans.
This might help to explain the previously observed
increased cardiovascular risk in chronically traumatized
individuals.
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Introduction
While alanine transaminase (ALT), aspartate transaminase
(AST), and alkaline phosphatase (ALP) are enzymes
located in tissues throughout the body, they are most often
increased as a result of liver injury, even in asymptomatic
patients [1]. As markers of liver damage, elevated levels of
ALT and AST typically reflect hepatocellular disease and
increased ALP levels are typically indicative for hepatob-
iliary disease [2, 3].
Experimental exposure to psychological stress impacts
liver structure in rodents, perhaps most evident in animals
with a coexistent liver or cardiovascular disease (CVD).
For instance, an aggressive encounter in male mice caused
increased plasma activities of ALT and AST after 3 h as
well as necrotic lesions of the liver parenchyma and
damage to hepatocytes 8 h later [4]. Electron microscopy
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showed autophagy of the liver compatible with hepatic
damage 2 days after exposure of rats to a variety of acute
stressors, including restraint stress [5]. Repeated cold-
immobilization stress for 5 days increased serum ALP
levels and was accompanied by liver failure in cardio-
myopathic hamsters but not in healthy control hamsters [6].
Oxidative damage to nuclear DNA of hepatocytes was
found in rats after 4 days of witnessing their mates being
electronically shocked [7]. To conclude, a recent review
proposed that psychological stress promotes a hepatic
inflammatory response that might contribute to the risk of
developing and aggravating several liver diseases [8].
Very few studies have actually addressed the potential
role of psychological stress in liver diseases in humans. In
patients with chronic alcoholic hepatitis, life stress was
associated with fibrosis and inflammatory changes [9]. In
Japanese workers, chronic job stress was associated with
elevated ALT levels, even when adjustment was made for
demographic, metabolic, and life style factors, including
alcohol intake [10]. Whether chronic psychological stress
prospectively predicts liver injury and elevation in liver
enzymes, respectively, has not been investigated in humans.
Posttraumatic stress disorder (PTSD) is a debilitating
form of chronic psychological stress that develops after
exposure to a traumatic event to which a person responded
with fear, helplessness, or horror [11]. Traditionally, PTSD
has been related to natural disasters and man-made trauma
such as combat exposure and sexual assaults [11]. However,
it is increasingly acknowledged that PTSD may occur in
relation to medical diagnoses and procedures such as in the
context of multiple physical trauma, severe burns, cancer,
and heart diseases [12–15]. Specifically, after an acute
myocardial infarction (MI), about 10% of patients develop
either full or subthreshold PTSD meeting Diagnostic and
Statistical Manual of Mental Disorders (DSM-IV) criteria
[16]. In addition to having experienced the life-threatening
heart attack as traumatic, the patients must have three dis-
tinct types of symptoms consisting of re-experiencing the
MI, avoidance of reminders of the MI, and hyperarousal
such as irritability and sleep disturbances for at least
1 month [11, 17]. Posttraumatic stress symptoms pro-
foundly impact daily functioning and may persist for many
years [11]. Of the 24 post-MI patients with DSM-IV PTSD
also investigated in the present study, two-thirds still
endorsed diagnostic PTSD, on average, 2 years later [18].
Posttraumatic stress disorder is associated with poor
physical health and particularly CVD [17, 19]. Military
veterans with PTSD initially free of CVD run a greater risk
for early age heart disease mortality [20]. The risk for
cardiovascular re-admissions was increased in patients who
had developed PTSD following MI, too [21]. A positive
screen for military sexual trauma was previously associated
with an increased risk of liver disease in US veterans [22].
However, whether PTSD relates to liver diseases has to our
knowledge not been investigated.
Carotid atherosclerosis is an inflammatory disease that
has been associated with non-alcoholic fatty liver disease
(NAFLD) [23] for which elevated levels of liver transam-
inases and ALP are markers [24]. Biomarkers of systemic
inflammation predict coronary heart disease (CHD) [25],
showed direct associations with ALT and ALP [26, 27],
and were also elevated in relation to symptoms of PTSD
[17, 28]. Elevated ALT predicted incident CHD after
10 years [29] and also coronary atherosclerosis in patients
with suspicious CHD, even after controlling for inflam-
mation and components of the metabolic syndrome [30].
Taken together, the above research implies that chronic
psychological stress might contribute to liver injury and
transaminases increase by kindling a hepatic and systemic
inflammatory response setting the stage for the initiation
and progression of atherosclerosis. Such psychopatho-
physiologic mechanisms might explain some of the excess
risk for incident CHD and recurrent CVD events in
chronically traumatized victims and post-MI patients,
respectively. We aimed to verify part of this notion to
ultimately better understand the biology of PTSD and its
physical health consequences. We studied the hypothesis
that diagnostic PTSD, which had developed after MI,
would prospectively predict plasma levels of ALT, AST,
and ALP after a mean follow-up of 2 years.
Materials and Methods
Study Participants
The study protocol was part of the ongoing longitudinal
Swiss Heart and Mind Study and approved by the ethics
committee of the State of Bern, Switzerland. All partici-
pants provided written informed consent. The recruitment
procedure has previously been detailed with regard to the
identification of the 24 patients with PTSD following an
index MI investigated in the present study [16, 18]. In brief,
all patients had been referred to the Department of Cardi-
ology, University of Bern, Switzerland, with a verified ST
elevation or non-ST elevation MI according to previous
guidelines [19] and had left ventricular ejection fraction
(LVEF) determined during coronary angiography. On
average, 3 ± 3 months (range 1–14) after the index MI, the
24 patients were mailed home the German version of the
self-rated posttraumatic diagnostic scale (PDS) [31] asking
about the 17 PTSD symptoms according to DSM-IV cri-
teria [32]. Based on meeting a predefined cut-off of PTSD
symptom severity on the PDS, they were invited to undergo
a structured interview applying the DSM-IV Clinician-
administered PTSD scale (CAPS) taking place on average
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4.2 ± 3.2 months (range 2–16) after the index MI.
According to the CAPS interview, eight patients had full
PTSD and 16 patients had subthreshold PTSD (cf. below).
Individual PTSD symptom clusters from the entry inter-
view, but not the total PTSD symptom score, were missing
in one participant.
Follow-Up Investigation
For the follow-up investigation presented here, the 24
patients were re-invited to the psychocardiology research
laboratory of the Cardiac Prevention and Rehabilitation,
University of Bern, Switzerland, between 1 and 3 years
after the initial diagnosis of PTSD. The investigation took
1  h and was scheduled to start after lunch between
12:30 p.m. and 2:00 p.m. Patients were asked to follow
their daily routine on the test day and to consume no heavy
meal for lunch. They were also asked to abstain from
smoking, alcoholic beverages, and sports activities starting
on the morning of the test day.
Upon arrival at the laboratory, participants first under-
went a structured medical history about past and current
diseases, current prescribed medications, and health habits.
Specifically, patients were asked about the number of
alcoholic drinks consumed in an average week, their sports
activities in hours performed in an average week, and
whether they currently smoked. After a resting period of at
least 15 min during which patients were sitting, blood
pressure (BP) was measured using sphygmomanometry. We
recorded BP three times with an interval of 5 min between
readings and computed the average of the three readings to
obtain screening systolic and diastolic BP. We measured
height and weight to compute the body mass index (BMI),
collected blood samples for the laboratory analyses and
performed the CAPS interview in the next sequence.
Clinician-Administered PTSD Scale
The clinician-administered PTSD Scale (CAPS) is a
structured psychometric interview allowing for a diagnosis
of PTSD as defined in the DSM-IV [33]. We applied the
German version of the CAPS showing good internal con-
sistency for the severity score of all 17 items of PTSD
(Cronbach’s a = .88–.92) and for each of the three PTSD
symptom clusters (a = .73–.88) [34]. The frequency and
intensity of each of the 17 PTSD symptoms are quantified
on a five-point scale ranging between e.g., ‘‘never’’ (0
points) to ‘‘almost always’’ (4 points). A particular symp-
tom is given when rated with a frequency of C1 point and
an intensity of C2 points. To meet diagnostic criteria for a
particular symptom cluster, criterion B (re-experiencing
subscale) requires one of five symptoms, criterion C
(avoidance subscale) requires three of seven symptoms,
and criterion D (hyperarousal subscale) requires two of five
symptoms. The CAPS symptom subscales provide a con-
tinuous measure of PTSD symptom severity. Overall
severity of PTSD is obtained by adding symptom scores of
criteria B plus C plus D to a total PTSD symptom score.
Full (i.e., syndromal) PTSD meets criteria B, C, and D, and
subthreshold (i.e., subsyndromal PTSD) meets criterion B
plus either C or D [35].
Laboratory Analyses
Venous blood samples were collected in appropriate tubes
and analyzed immediately within the clinical routine at the
Institute of Clinical Chemistry, University Hospital Bern,
Switzerland, applying standard laboratory procedures
(certified ISO/ICE). A Modular P800 system with ion
selective electrodes and Cobas standard test kits (all Roche
Diagnostics, Rotkreuz, Switzerland) were used to deter-
mine levels of liver enzymes and lipids in plasma. Gly-
cosylated hemoglobin A1c (HbA1c) was measured by
high-performance liquid chromatography on a HLC-723
G7 analyzer (Tosoh Corporation, Tokyo, Japan).
Statistical Analysis
Data analysis used SPSS 15.0 statistical software package
(SPSS Inc. Chicago, IL) with significance level set at
p \ .05 (two-tailed). Because several variables were not
normally distributed, we applied non-parametric statistics
throughout. For clarity, all data are provided in original
units, except in figures which show transformed values.
Specifically, we used the Mann–Whitney U test and Fish-
er’s exact test to test for differences between two groups in
continuous and categorical data, respectively. The Spear-
man rank test was used to estimate the crude correlation
between two variables. Blom normal score transformed
variables were used to compute partial correlation coeffi-
cients with 95% confidence intervals. Given the sample
size, we allowed for a maximum of two control variables
a priori in order to prevent overfitting of statistical models
[36]. These were the duration of follow-up and use of
antidepressant medication if being significantly associated
with liver enzymes in the crude correlation analysis. A
longer duration of PTSD might be expected to have a
greater impact on liver function and patients with more
severe PTSD might more readily be prescribed antide-
pressants, which, in turn, may cause elevation of liver
enzymes. We did not correct p-values for multiple tests
because in our case of a preestablished hypothesis (i.e.,
direct relationship between PTSD severity and enzyme
levels), this might deem truly important associations
insignificant, thereby misleading future studies in a still
nascent area of research [37].
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Results
Subject Characteristics
Table 1 shows the demographic, metabolic, and health
behavior variables of the 24 patients at follow-up. Plasma
levels of liver enzymes were, on average, in the normal
laboratory range. However, taking into account age and sex
of individual patients, three exceeded the upper normal
reference range for both ALT and AST, whereas one
exceeded the upper normal reference range for AST only.
Table 2 shows the medication list of study participants at
follow-up. Particularly, all patients had lipid lowering
therapy (statins in 23 of cases) and four patients were
prescribed antidepressants.
During the follow-up period, no acute cardiovascular
events had occurred requiring hospital admission. Three
patients had undergone elective coronary stenting. Two
patients who were also on antidepressants had psycho-
therapy without trauma-specific elements.
Associations with Liver Enzymes
Transaminases correlated with each other (r = .62,
p = .002), but not significantly with ALP. Alanine trans-
aminase correlated with age (r = -.50, p = .015) and was
higher in patients with a history of diabetes than in those
without (53.0 ± 29.7 vs. 26.9 ± 12.2 U/l, p = .026). No
other associations emerged between any other demo-
graphic, metabolic, and life style factor shown in Table 1 on
the one hand and ALT, AST, and ALP levels on the other
(all p-values [.05). In particular, no association emerged
between LVEF and liver enzymes (p-values[.59). In terms
of medication, the four patients on antidepressants had
higher plasma levels of ALT (51 ± 27 vs. 26 ± 12 U/l,
p = .009) and of AST (42 ± 12 vs. 28 ± 6 U/l, p = .029)
than the 20 patients not taking antidepressants. Liver
enzymes showed no significant correlation with any other
medication category listed in Table 2 (all p-values[.05).
Posttraumatic Stress Symptoms
The mean follow-up was 26.2 ± 6.5 months (range 12–36),
during which there was a significant decrease in the total
PTSD symptom score (53.0 ± 21.6 vs. 36.3 ± 26.5,
p = .001), re-experiencing symptoms (18.3 ± 7.5 vs.
10.6 ± 8.5, p \ .001), avoidance symptoms (18.7 ± 9.8
vs. 13.8 ± 13.1, p = .015), but not in hyperarousal symp-
toms (16.7 ± 7.6 vs. 13.2 ± 8.0, p \ .06). Of the 24 post-
MI patients with a diagnosis of PTSD at study entry, 16 still
fulfilled the diagnostic criteria for PTSD at follow-up.
Posttraumatic Stress Symptoms and Liver Enzymes
PTSD Symptoms at Study Entry and Liver Enzymes
With adjustment to the duration of follow-up and antide-
pressant use, the total score of PTSD symptoms assessed at
study entry significantly predicted ALT (Fig. 1a) and ALP
(Fig. 3a) to explain 22 and 32% of the respective variance
Table 1 Characteristics of the 24 myocardial infarction patients
Male (%) 79
Age (years) 58.6 ± 6.7 (45–74)
Left ventricular ejection fraction (%) 52.1 ± 9.4 (25–65)
Body mass index (kg/m2) 27.7 ± 3.7 (20.1–36.8)
Total cholesterol (mmol/l) 4.0 ± .9 (2.2–6.5)
Triglycerides (mmol/l) 1.7 ± 1.1 (.5–5.9)
Hemoglobin A1c (%) 6.0 ± .8 (5.3–9.0)
Type II diabetes (%) 13
Systolic blood pressure (mmHg) 124 ± 15 (99–150)
Diastolic blood pressure (mmHg) 83 ± 9 (55–100)
Treated for systemic hypertension (%) 96
Alcohol consumption (drinks/week) 5.0 ± 6.2 (0–21)
Sports activities (h/week) 4.2 ± 3.0 (0–9)
Current smoker (%) 21
Alanine transaminase (U/l) 30.3 ± 17.0 (11–87)
Aspartate transaminase (U/l) 30.2 ± 9.1 (17–56)
Alkaline phosphatase (U/l) 64.2 ± 20.7 (24–108)
Values are given as means ± SD with range or percentages
Table 2 Medication list of the 24 study participants
Statins (%) 96
Other lipid lowering drugs (%) 12
Aspirin (%) 96
Clopidogrel (%) 29
Phenprocoumon (%) 4
Insulin (%) 4
Oral antidiabetics (%) 4
Beta blockers (%) 87
Angiotensin converting enzyme inhibitors (%) 42
Angiotensin II receptor blockers (%) 25
Calcium antagonists (%) 21
Diuretics (%) 25
Amiodarone (%) 8
Levothyroxine (%) 8
Tamoxifen (%) 4
Pain medication (%) 25
Antidepressants (%) 17
Benzodiazepines (%) 4
Values are given as percentages referring to the population of all 24
patients
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(Table 3). In contrast, the total PTSD symptom score at
entry was not a significant predictor of AST (p = .15).
Table 3 further shows that of the individual PTSD
symptom clusters assessed at study entry, re-experiencing
symptoms significantly predicted ALT (Fig. 1b) and ALP
(Fig. 3b), explaining 27 and 26% of the respective vari-
ance. Avoidance symptoms significantly predicted ALT
(Fig. 1c), AST (Fig. 2a), and ALP (Fig. 3c) to account for
21, 19, and 40% of respective variances. Eventually,
hyperarousal symptoms significantly explained 19% of the
variance of both AST (Fig. 2b) and ALP (Fig. 3d).
PTSD Symptoms at Follow-Up and Liver Enzymes
Neither the total PTSD symptom score nor individual
symptom clusters assessed at follow-up were significantly
associated with any liver enzyme in all 24 patients with
adjustment for duration of follow-up and antidepressant use
(Table 3). However, in the subgroup of the 16 patients who
still had diagnostic PTSD in the follow-up interview, the
total follow-up score of PTSD symptoms correlated with
ALT (p = .004), AST (p = .018), and ALP (p = .001),
taking into account the duration of follow-up. Symptom
clusters of avoidance (p-values\.032) and of hyperarousal
(p-values \.027) were both associated with each liver
enzyme; the re-experiencing cluster was also associated
with ALT (p = .018), but not with AST (p = .27) and ALP
(p = .53). The analysis in the 16 patients with diagnostic
PTSD did not adjust for the use of antidepressants because
only two patients were on these medications.
Discussion
We showed that the severity of PTSD, which had devel-
oped in the aftermath of an acute MI, was a significant
predictor of plasma levels of ALT and ALP assessed, on
average, 2 years after the diagnosis of PTSD. The analysis
adjusted for the duration of follow-up and thereby
accounted for the possibility that the mere duration of
PTSD rather than its severity would impact liver function
and structure. We also adjusted for antidepressants which,
as seen in our patient group, are well known to increase
transaminases levels. In contrast to ALT and ALP, we did
not find that the severity of PTSD was a prospective pre-
dictor of AST.
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Fig. 1 Scatter plot with fit line showing the significant associations
between alanine transaminase (ALT) and study entry scores for total
PTSD symptoms (a; p = .031), re-experiencing symptoms
(b; p = .018), and avoidance symptoms (c; p = .043). Adjustment
was made for the duration of follow-up and antidepressant use (yes
vs. no). Values are given as normal scores
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The analysis of individual symptom clusters revealed
that the non-significant relationship between PTSD severity
at entry and AST was for the most part accounted for by the
lack of an association between re-experiencing symptoms
and AST. Re-experiencing symptoms predicted ALT and
ALP, hyperarousal symptoms were predictive for AST and
ALP, and symptoms of avoidance predicted plasma levels
of all enzymes. The correlation coefficients of the rela-
tionships between the various PTSD symptom scores and
enzyme levels were quite similar in absolute terms.
Therefore, we feel it premature to propose any symptom
cluster to be a more reliable predictor of liver enzyme levels
than any other. Given the relatively small sample, a type II
error of failing to observe a true relationship also cannot be
ruled out. Accordingly, there were considerably wide con-
fidence intervals around the observed partial correlation
coefficients. Nevertheless, variances in plasma levels of
liver enzymes explained by the various PTSD scores were
between 19 and 40%, suggesting that these relationships
were not only statistically but also clinically meaningful.
As previously reported, while all PTSD symptom scores
except hyperarousal had significantly decreased over time,
Table 3 Associations between posttraumatic stress symptom scores and liver enzymes
Alanine transaminase Aspartate transaminase Alkaline phosphatase
Entry scores (all patients; n = 24)
PTSD total score .47 (.08–.74)* .32 (-.10–.65) .57 (.22–.80)**
Re-experiencing cluster .52 (.15–.77)* .16 (-.27–.53) .51 (.14–.77)*
Avoidance cluster .46 (.07–.74)* .44 (.04–.72)* .63 (.31–.83)**
Hyperarousal cluster .43 (.03–.72) .44 (.04–.72)* .44 (.04–.72)*
Follow-up scores (all patients; n = 24)
PTSD total score .07 (-.35–.46) .002 (-.41–.41) .23 (-.19–.58)
Re-experiencing cluster .05 (-.37–.45) -.08 (-.47–.34) .07 (-.35–.46)
Avoidance cluster -.03 (-.43–.38) .10 (-.32–.49) .28 (-.14–.62)
Hyperarousal cluster .24 (-.18–.59) .04 (-.38–.44) .33 (-.08–.65)
Follow-up scores (patients with PTSD at follow-up; n = 16)
PTSD total score .72 (.35–.90)** .60 (.15–.85)* .64 (.21–.86)*
Re-experiencing cluster .61 (.17–.85)* .30 (-.23–.70) .18 (-.35–.63)
Avoidance cluster .58 (.12–.84)* .65 (.23–.87)** .69 (.29–.89)**
Hyperarousal cluster .79 (.49–.93)** .57 (.10–.84)* .60 (.15–.85)*
The columns show the partial correlation coefficients (95% confidence interval) with significance level after adjustment for the duration of
follow-up. Alanine transaminase and aspartate transaminase were additionally adjusted for antidepressant use in all 24 patients with PTSD at
study entry
PTSD posttraumatic stress disorder
Significance level: * p \ .05, ** p \ .01
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Fig. 2 Scatter plot with fit line showing the significant associations
between aspartate transaminase (AST) and study entry scores for
symptoms of avoidances (a; p = .049) and of hyperarousal
(b; p = .044). Adjustment was made for the duration of follow-up
and antidepressant use (yes vs. no). Values are given as normal scores
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two-thirds of post-MI patients still had diagnostic PTSD at
follow-up, which indicates that PTSD related to MI is a
considerably persistent stress disorder [18]. Pertinent to the
present study, follow-up scores of total PTSD symptoms
and of virtually all individual PTSD symptom clusters
showed only a significant association with ALT, AST, and
ALP in the two-thirds of patients who maintained PTSD.
This suggests that even though PTSD severity waned over
time, with some individuals even remitting, the long-term
effect of an initial diagnosis of PTSD on liver enzymes was
sustained. In contrast, PTSD symptomatology had to fulfill
criteria of diagnostic PTSD at follow-up in order to reveal a
steady-state association between PTSD severity and liver
enzymes. However, PTSD patients have a greater degree of
sympathetic nervous system activation [11]. In rats, trans-
aminases were significantly increased 3 h after acute psy-
chological stress [4]. We can therefore not rule out the
possibility that anticipatory appraisal of the CAPS inter-
view as overly threatening might have elicited an increase
in liver enzymes in relation to PTSD severity.
Our finding of PTSD predicting circulating levels of
hepatic enzymes are in accordance with considerably
consistent literature about psychological stress causing
liver injury and an increase in hepatic enzymes in rodents
[4–7]. Our data also concur with cross-sectional associa-
tions between chronic life stress and the degree of chronic
hepatitis and ALT levels in humans [9, 10]. Although not
investigated in our study, PTSD might provoke hepatic
inflammation and liver injury primordially through
peripheral effectors of the stress response, namely cate-
cholamines and glucocorticoids. Noradrenergic dysregula-
tion plays a major role in the initiation and maintenance of
hyperarousal and reexperiencing symptoms of PTSD [38].
Moreover, military veterans with PTSD showed increased
circulating levels of norepinephrine [39] and greater
increase in plasma norepinephrine to trauma-specific
stimuli [40]. In rodents, footshock stress enhanced chemi-
cally induced liver damage; this effect was partially med-
iated via released catecholamines [41]. Immobilization
stress increased interleukin (IL)-6 production in hepato-
cytes and also elevated plasma IL-6 levels [42]. Hepato-
cytes and hepatic nonparenchymal cells incubated with
norepinephrine in vitro produced IL-6 and IL-1b, respec-
tively [43]. In addition to catecholaminergic hyperactivity,
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Fig. 3 Scatter plot with fit line showing the significant association
between alkaline phosphatase (ALP) and study entry scores for total
PTSD symptoms (a; p = .004), re-experiencing symptoms
(b; p = .016), avoidance symptoms (c; p = .002), and hyperarousal
symptoms (d; p = .040). Adjustment was made for the duration of
follow-up. Values are given as normal scores
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PTSD patients show a hypocortisolism consequent to a
dysregulated hypothalamic–pituitary–adrenal (HPA) axis
[11, 44]. Glucocorticoids inhibit the production of proin-
flammatory cytokines by liver macrophages, supporting the
assumption that endogenous glucocorticoid deficiency
accompanying psychological stress might promote macro-
phage production of IL-1, IL-6, and tumor necrosis factor-a
[45]. Taken together, increased sympathetic outflow to the
liver and hypocortisolism provide plausible mechanisms
potentially underlying higher levels of liver enzymes in our
post-MI patients with more severe PTSD.
It has been proposed that mild increases in liver enzyme
levels indicate systemic inflammation that emanates from
hepatic inflammation and particularly NAFLD [26]. Sys-
temic inflammation such as related to NAFLD is key to the
extent and severity of atherosclerosis [46]. Even when
controlling for metabolic factors, NAFLD was an inde-
pendent predictor of CVD, suggesting its unique role as a
cardiometabolic risk factor [47]. The probability of histo-
logically verified NAFLD increases with higher levels of
ALT [48], which, in turn, was predictive for CHD [29, 30].
Except for a history of diabetes, metabolic factors and
alcohol consumption did not significantly correlate with
liver enzymes in our patients. Since diabetes was present in
only three subjects, it was inappropriate to test whether
diabetes would mediate the relationship between PTSD and
ALT levels. On the whole, we found that the increase in
liver enzymes related to PTSD was for the most part
unrelated to metabolic factors, suggesting that elevated
ALT could be a biomarker of increased cardiovascular risk
related to PTSD in post-MI patients [21].
Our study has several limitations. The sample size
unfortunately precluded adjustment for more than two
covariates. Note that these were selected a priori based on
scientific grounds (i.e., longer duration of PTSD might
more severely impact liver function and antidepressants
would increase liver enzymes). With the sample size at
hand, we were already slightly below the minimum ratio
of 10:1 for participants to observed variables in models
that included three dependent variables. This ratio is
commonly recommended to prevent overfitted models
with biased partial correlation coefficients [36]. Particu-
larly age and history of diabetes correlated with ALT in
the bivariate analysis and might be important confound-
ers, although analyses in larger samples will have to test
this. In terms of variables that did not correlate with liver
enzymes individually, these might explain the consider-
able variance of relationships if aggregated and applied to
a larger sample. We are unable to state which amount of
enzyme activity is of hepatic origin and which quantity
derives from other tissues. For instance, we did not assess
isoforms of ALP, particularly its bone fraction. Moreover,
AST is less specific for hepatic damage than ALT. This
might partially explain why the total PTSD symptom
score assessed at study entry predicted ALT but not AST.
We investigated liver enzymes in relation to PTSD that
had occurred post-MI. Whether similar relationships are
found in healthy individuals and medical patients with
PTSD that emerged after different types of trauma
remains to be seen. The clinical relevance of our findings
might be challenged by the fact that only a few patients
exceeded the upper reference range for enzyme levels;
however, virtually all patients had statins which, for
instance, lower mildly elevated AST levels [49]. We did
not perform liver biopsy and ultrasound to exclude
chronic liver disease or biliary obstruction. Particularly,
we did not conduct a background work-up for the pres-
ence of NAFLD, chronic viral hepatitis, and hemochro-
matosis. However, this drawback might be assumed to not
have inflated substantial bias into our findings, since there
is currently no evidence that these rather rare conditions
should be overly prevalent in patients with PTSD. We
also did not measure enzyme levels at study entry and
therefore we were unable to estimate the relationship
between trajectories in PTSD and liver enzyme levels
over time. This weakness of the study design evidently
limits our estimate of a prospective association between
PTSD symptomatology and liver enzymes.
To sum up, we found that PTSD severity following MI
was associated with elevation of plasma levels of liver
enzymes, suggesting that chronic psychological stress
predicts liver injury in humans. Given that mildly elevated
levels of liver enzymes are markers of hepatic and systemic
inflammation alike, our findings provide one psychobio-
logical mechanism by which PTSD might contribute to
CVD. To further elucidate such a theory, future studies
may want to investigate whether NFALD shows an asso-
ciation with chronic psychological stress and PTSD in
particular. To better understand the biology of PTSD, it
also seems worthwhile to investigate whether liver
enzymes mediate or moderate an association between
NFALD and CVD in healthy individuals and post-MI
patients with PTSD.
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